Welcome to our dedicated page for NEKTAR THERAPEUTICS SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Vanguard Capital Management reports beneficial ownership of Nektar Therapeutics common stock. Vanguard and certain affiliated entities collectively hold 1,747,653 shares of Nektar common stock, representing 5.17% of the class as of June 30, 2026.
Within this position, Vanguard has sole voting power over 250,804 shares and sole dispositive power over 1,747,653 shares, with no shared voting or dispositive power reported. The holdings include securities in Vanguard funds and managed accounts over which Vanguard or its specified affiliates exercise voting and/or dispositive authority. No other single person’s interest in these securities exceeds 5% of the class.
BlackRock, Inc. reported beneficial ownership of 2,643,796 shares of NEKTAR THERAPEUTICS common stock on a Schedule 13G, representing 7.8% of the outstanding class as of June 30, 2026. BlackRock has sole voting power over 2,590,855 shares and sole dispositive power over 2,643,796 shares, with no shared voting or dispositive power.
The holdings are attributed to certain BlackRock business units, and the economic interest in these shares is spread among various underlying clients. No single underlying person is reported to hold more than five percent of NEKTAR THERAPEUTICS’ outstanding common shares.
Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky received a grant of stock options covering 16,500 shares of common stock at an exercise price of $15.1500 per share, expiring on 2032-12-12. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan with both performance-based and time-based vesting. The Organization and Compensation Committee determined on July 23, 2026 that the performance condition was satisfied, and the options vested on July 24, 2026, subject to continued monthly pro-rata time-based vesting over five years from the grant date.
Howard W. Robin, President & CEO of Nektar Therapeutics, reported an acquisition of 57,200 stock options linked to common stock. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan, have a $15.15 exercise price, and expire on December 12, 2032. The Organization and Compensation Committee determined on July 23, 2026 that the performance-based vesting requirement was satisfied and stated that the options vested on July 24, 2026, while time-based vesting continues on a monthly pro-rata basis over five years from the grant date.
Nektar Therapeutics’ Chief R&D Officer, Jonathan Zalevsky, sold 5,681 shares of Common Stock in an open-market transaction at $70.00 per share. After this sale, he directly holds 9,756 shares. The sale was executed on June 30, 2026 and was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
Jonathan Zalevsky reported sales of 5,737 shares of Common Stock under a pre-arranged 10b5-1 plan.
The filing lists two transactions: 05/19/2026 sale of 199 shares for $13,036.49, and 06/15/2026 sale of 5,538 shares for $336,190.38. The record also shows 5,681 Restricted Stock Units dated 11/15/2020 with a reference date of 06/30/2026.
Nektar Therapeutics President & CEO Howard W. Robin reported open-market sales of 20,000 shares of common stock over two days in mid-June 2026. On June 16, 2026, he sold 5,303 shares at $59.97 and 4,697 shares at $60.71. On June 17, 2026, he sold 5,500 shares at $60.81 and 4,500 shares at $61.65. A footnote states that at least one transaction was made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating the sales were pre-arranged. After these transactions, Robin directly owns 55,045 Nektar shares, and an additional 28 shares are held indirectly by his spouse.
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,538 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $60.71 per share on June 15, 2026, in multiple trades between $60.06 and $61.36.
After this sale, Zalevsky directly holds 15,437 shares of Nektar Therapeutics common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 13, 2026, indicating the sale was pre-arranged rather than timed discretionarily.
Nektar Therapeutics insider filing (Form 144) reports proposed sales. The notice lists two recent dispositions: 444 shares sold on 05/19/2026 for $29,084.53 and 10,000 shares sold on 06/16/2026 for $603,137.31. The filing also lists multiple Restricted Stock Vesting entries with specific vested share counts and dates.
NKTR: Notice of proposed insider sale and restricted‑stock vesting activity. The excerpt lists a proposed sale of 10,000 shares and related figures tied to the security, plus multiple past and scheduled restricted stock vesting events (examples: 2,991 vesting on 08/15/2025, 1,860 on 11/15/2021). The filing also records a sale by Howard Robin of 444 shares for $29,084.53.